Antoine GUERIN Unité Inserm 1163 IHU Imagine Laboratoire de génétique humaine des maladies infectieuses Team "Génétique immunologique" +33 (0)1 42 75 43 97 email@example.com
A Franco-American team involving researchers from Inserm, Université Paris-Descartes and doctors grouped in the Institute Imagine the hospital Necker-Enfants Malades AP-HP and Rockefeller University New York discovered a genetic cause of Whipple’s disease, chronic intestinal pathology. By studying families with 4 members developed symptoms, the team found that the mutation of the gene causes IRF4 an impaired immune response to the bacteriaTropheryma whippleiAt the origin of the disease.This bacterium, common and experienced by many individuals, then causes in carriers of the mutation potentially fatal chronic infection without treatment. With this discovery, the first step towards a genetic explanation of the disease was done.
Chronic bacterial infection, Whipple’s disease occurs around the age of 50 and may result in clinical signs such as diarrhea, malabsorption, fever, weight loss, joint diseases, cardiovascular or central nervous system. In the absence or failure of antibiotic treatment, it can progress to death.
The disease is caused by Tropheryma whipplei , a bacterium that many of us encounter in our life (up to 50% of the members of some populations are carriers), but which affects a very small portion of individuals: only a subject on a million developing the symptoms of the disease.
The team led by Professor Jean-Laurent Casanova, laboratory director of Human Genetics of Infectious Diseases at the Institute. Imagine – Inserm, Paris Descartes University, AP-HP-member of Immunology, Hematology and Pediatric Rheumatology Hospital Necker Children AP-HP, Dr. Jacinta Bustamante, a research professor in the same laboratory and within the diagnostic center immune deficiencies at the Hospital Necker Children AP-HP, and Dr. Laurent Abel, co-director of the laboratory of human genetics of infectious diseases at Imagine , found that many families have multiple members affected by the disease, suggesting a genetic origin.
With this study and the discovery of this mutation, the research team laid the foundation stone for a genetic understanding of the disease. Sequencing of a cohort of patients has not found other mutations in the same gene showing genetic heterogeneity of the disease. It remains to find and understand the mechanism immune deficiency caused by the mutation of the gene and to find other genetic mutations that may explain the vulnerability to disease.
This breakthrough helps explain why some patients exposed to the bacteria are sick or not, improve diagnosis, genetic counseling to families and the care of patients with the signs of the disease.
(Français) Des chercheurs de Généthon, le laboratoire de l’AFM-Téléthon, et de l'Inserm, en collaboration avec la biotech américaine Selecta Biosciences, démontrent la possibilité de ré-administrer une thérapie génique par vecteur AAV (virus adéno-associé), sans réponse immunitaire, grâce à des nanoparticules de rapamycine, ...
To become the most advanced and competitive genomics research and healthcare system in the world: such was the ambition declared by Inserm, and its partners Aviesan and Genomics England Ltd, during the UK-France Summit on January 18, 2018. An agreement was signed ...